Market Research Report

Product code

936473

Global Submental Fat Treatment Market - Industry Trends and Forecast to 2027

Published: April 1, 2020 |

Data Bridge Market Research Private Limited | 203 Pages | Delivery time: Inquiry

Price

Description
Table of Contents
List of Tables

Add to Compare

Global submental fat treatment market is projected to register a substantial CAGR of 13.2% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027

Market Segmentation

Global Submental Fat Treatment Market By Type (Invasive Method, Minimally Invasive & Non Invasive Technology), End User (Cosmetic Centers, Hospitals, Dermatology Clinics, Medical Spa, Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and Rest of Middle East and Africa) Industry Trends & Forecast to 2027.

Some of the major factors contributing to the growth of the global submental fat treatment market are:

Rising prevalence of obesity

Increased reliability on liposuction procedure

Market Players

The key market players for global submental fat treatment market are listed below:

Allergan plc

CANDELA CORPORATION

Cynosure LLC

Lumenis

INMODE

Cutera

Laser Lipo Ltd

Solta Medical

ERCHONIA CORPORATION

ThermiGen, LLC.

BTL Group of Companies

Alma Lasers (A Subsidiary of Sisram Medical Ltd)

HIRONIC CO., LTD.

ENDYMED MEDICAL

1 INTRODUCTION 22

1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF GLOBAL SUBMENTAL FAT TREATMENT MARKET 23
1.4 CURRENCY AND PRICING 24
1.5 LIMITATIONS 24
1.6 MARKETS COVERED 24

2 MARKET SEGMENTATION 27

2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 DBMR TRIPOD DATA VALIDATION MODEL 30
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.6 MULTIVARIATE MODELLING 34
2.7 TYPE LIFELINE CURVE 34
2.8 DBMR MARKET POSITION GRID 35
2.9 MARKET APPLICATION COVERAGE GRID 37
2.10 VENDOR SHARE ANALYSIS 37
2.11 SECONDARY SOURCES 38
2.12 ASSUMPTIONS 38

3 EXECUTIVE SUMMARY 39

4 INDUSTRY INSIGHTS 44

4.1 REIMBURSEMENT SCENARIO 44

5 MARKET OVERVIEW 45

5.1 DRIVERS 47
- 5.1.1 INCREASING AWARENESS FOR COSMETIC PROCEDURES AMONG PEOPLE 47
- 5.1.2 RISING PREVALENCE OF OBESITY 47
- 5.1.3 INCREASING DEMAND FOR MINIMALLY INVASIVE PROCEDURES 48
- 5.1.4 INCREASED RELIABILITY ON LIPOSUCTION PROCEDURE 49
- 5.1.5 AVAILABILITY OF ADVANCED AND USER FRIENDLY PRODUCTS 49
5.2 RESTRAINTS 50
- 5.2.1 HIGH COST OF PROCEDURES 50
- 5.2.2 INCREASED RISKS ASSOCIATED WITH THE PROCEDURES 50
- 5.2.3 STRINGENT REGULATIONS FOR APPROVAL OF PRODUCTS 51

5.3 OPPORTUNITIES 52
- 5.3.1 EVOLUTION IN LASER AND RF DEVICES 52
- 5.3.2 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR COSMETIC PROCEDURES 53
- 5.3.3 INTRODUCTION OF NOVEL NON- INVASIVE TECHNOLOGY 53
5.4 CHALLENGES 54
- 5.4.1 INCREASED RECOVERY TIME OF PROCEDURES 54
- 5.4.2 REQUIREMENT OF MULTIPLE SESSIONS FOR GETTING MAXIMUM RESULTS 54

6 GLOBAL SUBMENTAL FAT TREATMENT MARKET, BY TYPE 55

6.1 OVERVIEW 56
6.2 MINIMALLY INVASIVE & NON-INVASIVE TECHNOLOGY 59
- 6.2.1 ULTRASOUND 59
- 6.2.2 CRYOLIPOLYSIS 60
- 6.2.3 RADIOFREQUENCY-ASSISTED CONTOURING 60
- 6.2.4 LOW-LEVEL LASERS 60
- 6.2.5 COMBINATION TREATMENT 60
- 6.2.6 INJECTABLE ADIPOCYTOLYSIS 60
- 6.2.7 OTHERS 60
6.3 INVASIVE METHOD 61
- 6.3.1 LIPOSUCTION 61
- 6.3.2 SURGICAL REJUVENATION 61
- 6.3.3 CHIN IMPLANT 61

7 GLOBAL SUBMENTAL FAT TREATMENT MARKET, BY END USER 62

7.1 OVERVIEW 63
7.2 COSMETIC CENTERS 66
7.3 HOSPITALS 66
7.4 DERMATOLOGY CLINICS 67
7.5 MEDICAL SPA 67
7.6 OTHERS 68

8 GLOBAL SUBMENTAL FAT TREATMENT MARKET, BY DISTRIBUTION CHANNEL 69

8.1 OVERVIEW 70
8.2 DIRECT TENDER 73
8.3 RETAIL SALES 73

9 GLOBAL SUBMENTAL FAT TREATMENT MARKET, BY GEOGRAPHY 74

9.1 OVERVIEW 75
9.2 NORTH AMERICA 80
- 9.2.1 U.S. 85
- 9.2.2 CANADA 87
- 9.2.3 MEXICO 89
9.3 EUROPE 91
- 9.3.1 GERMANY 96
- 9.3.2 FRANCE 98
- 9.3.3 ITALY 100
- 9.3.4 U.K. 102
- 9.3.5 SPAIN 104
- 9.3.6 RUSSIA 106
- 9.3.7 NETHERLANDS 108
- 9.3.8 SWITZERLAND 110
- 9.3.9 BELGIUM 112
- 9.3.10 TURKEY 114
- 9.3.11 REST OF EUROPE 116
9.4 ASIA-PACIFIC 117
- 9.4.1 JAPAN 122
- 9.4.2 CHINA 124
- 9.4.3 AUSTRALIA 126
- 9.4.4 SOUTH KOREA 128
- 9.4.5 SINGAPORE 130
- 9.4.6 INDIA 132
- 9.4.7 MALAYSIA 134
- 9.4.8 THAILAND 136
- 9.4.9 INDONESIA 138
- 9.4.10 PHILIPPINES 140
- 9.4.11 REST OF ASIA-PACIFIC 142
9.5 SOUTH AMERICA 143
- 9.5.1 BRAZIL 148
- 9.5.2 ARGENTINA 150
- 9.5.3 REST OF SOUTH AMERICA 152
9.6 MIDDLE EAST & AFRICA 153
- 9.6.1 SAUDI ARABIA 158
- 9.6.2 SOUTH AFRICA 160
- 9.6.3 U.A.E. 162
- 9.6.4 ISRAEL 164
- 9.6.5 EGYPT 166
- 9.6.6 REST OF MIDDLE EAST & AFRICA 168

10 GLOBAL SUBMENTAL FAT TREATMENT MARKET, COMPANY LANDSCAPE 169

10.1 COMPANY SHARE ANALYSIS: GLOBAL 169
10.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 170
10.3 COMPANY SHARE ANALYSIS: EUROPE 171
10.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 172

11 SWOT & DATA BRIDGE MARKET RESEARCH ANALYSIS 173

11.1 SWOT ANALYSIS 173
- 11.1.1 STRENGTH: - SIGNIFICANT GROWTH OF SHARES IN MARKET FOCUSED SEGMENT 173
- 11.1.2 STRENGTH: - FOCUSED ON AESTHETIC SOLUTIONS 173
- 11.1.3 WEAKNESS: DEPENDENCE ON SUPPLIERS/ DISTRIBUTORS 174
- 11.1.4 OPPORTUNITY: - STRATEGIC INITIATIVES FOR BUSINESS EXPANISION BY PRODUCT LAUNCH, ACQUISITION AND OTHERS 174
- 11.1.5 THREAT: - CURRENCY FLUCTUATION 175
11.2 DATA BRIDGE MARKET RESEARCH ANALYSIS 175

12 COMPANY PROFILE 176

12.1 ALLERGAN 176
- 12.1.1 COMPANY SNAPSHOT 176
- 12.1.2 REVENUE ANALYSIS 177
- 12.1.3 COMPANY SHARE ANALYSIS 177
- 12.1.4 PRODUCT PORTFOLIO 178
- 12.1.5 RECENT DEVELOPMENTS 178
12.2 INMODE 179
- 12.2.1 COMPANY SNAPSHOT 179
- 12.2.2 REVENUE ANALYSIS 180
- 12.2.3 COMPANY SHARE ANALYSIS 180
- 12.2.4 PRODUCT PORTFOLIO 181
- 12.2.5 RECENT DEVELOPMENT 181
12.3 HIRONIC CO., LTD. 182
- 12.3.1 COMPANY SNAPSHOT 182
- 12.3.2 REVENUE ANALYSIS 182
- 12.3.3 COMPANY SHARE ANALYSIS 183
- 12.3.4 PRODUCT PORTFOLIO 183
- 12.3.5 RECENT DEVELOPMENT 183
12.4 CANDELA CORPORATION 184
- 12.4.1 COMPANY SNAPSHOT 184
- 12.4.2 COMPANY SHARE ANALYSIS 184
- 12.4.3 PRODUCT PORTFOLIO 185
- 12.4.4 RECENT DEVELOPMENT 185
12.5 CYNOSURE LLC 186
- 12.5.1 COMPANY SNAPSHOT 186
- 12.5.2 PRODUCT PORTFOLIO 186
- 12.5.3 RECENT DEVELOPMENTS 186

12.6 BTL GROUP OF COMPANIES 187
- 12.6.1 COMPANY SNAPSHOT 187
- 12.6.2 SOLUTION PORTFOLIO 187
- 12.6.3 RECENT DEVELOPMENTS 187
12.7 ALMA LASERS (A SUBSIDIARY OF SISRAM MEDICAL LTD) 188
- 12.7.1 COMPANY SNAPSHOT 188
- 12.7.2 REVENUE ANALYSIS 188
- 12.7.3 PRODUCT PORTFOLIO 189
- 12.7.4 RECENT DEVELOPMENTS 189
12.8 ENDYMED MEDICAL 190
- 12.8.1 COMPANY SNAPSHOT 190
- 12.8.2 REVENUE ANALYSIS 190
- 12.8.3 PRODUCT PORTFOLIO 191
- 12.8.4 RECENT DEVELOPMENT 191
12.9 CUTERA 192
- 12.9.1 COMPANY SNAPSHOT 192
- 12.9.2 REVENUE ANALYSIS 193
- 12.9.3 PRODUCT PORTFOLIO 193
- 12.9.4 RECENT DEVELOPMENT 193
12.10 ALASTIN SKINCARE, INC. 194
- 12.10.1 COMPANY SNAPSHOT 194
- 12.10.2 PRODUCT PORTFOLIO 194
- 12.10.3 RECENT DEVELOPMENTS 194
12.11 ERCHONIA CORPORATION 195
- 12.11.1 COMPANY SNAPSHOT 195
- 12.11.2 PRODUCT PORTFOLIO 195
- 12.11.3 RECENT DEVELOPMENT 195
12.12 LASER LIPO LTD. 196
- 12.12.1 COMPANY SNAPSHOT 196
- 12.12.2 PRODUCT PORTFOLIO 196
- 12.12.3 RECENT DEVELOPMENT 196
12.13 LUMENIS 197
- 12.13.1 COMPANY SNAPSHOT 197
- 12.13.2 PRODUCT PORTFOLIO 197
- 12.13.3 RECENT DEVELOPMENT 197
12.14 SOLTA MEDICAL 198
- 12.14.1 COMPANY SNAPSHOT 198
- 12.14.2 BRAND PORTFOLIO 198
- 12.14.3 RECENT DEVELOPMENT 198

12.15 THERMIGEN, LLC. 199
- 12.15.1 COMPANY SNAPSHOT 199
- 12.15.2 PRODUCT PORTFOLIO 199
- 12.15.3 RECENT DEVELOPMENT 199

13 QUESTIONNAIRE 200

14 CONCLUSION 202

15 RELATED REPORTS 203

LIST OF TABLES